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We evaluated the elimination of COZ in three Japanese adults with carbonic anhydrase II (CA II) deficiency, as 
compared with that in 10 healthy volunteers. The patients had no signs of respiratory distress. Heart rate, body 
temperature, ventilation volume, respiratory rate and (a - ET) PC02 were found to be higher and PaCOZ tended to 
be higher in the patients than those in the volunteers, while forced vital capacity (FVC), forced expiratory volume in 
1s (FEV,), tidal volume, end-tidal PC02 (PETCO~), pH and HC03- in arterial blood were lower in the patients. All 
three patients had non-anion-gap metabolic acidosis, due to renal losses of bicarbonate, but with virtually no 
compensatory reduction in PaC02. However, the high QE and Pa02 suggested that respiratory compensation for 
this metabolic acidosis was occuring, the elimination of COZ was possibly facilitated by the presence of other 
carbonic anhydrase isoenzymes in the pulmonary capillaries. Thus, CA II deficiency causes mild to moderate 
impairments in CO2 elimination. 
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Introduction 
Three Japanese patients with a carbonic anhydrase II 
(CAII) deficiency were previously reported to have renal 
tubular acidosis, a disturbance in calcium metabolism with 
cerebral calcifications, osteopetrosis and mental problems 
(l-3). Ohlsson et al. have previously reported a restrictive 
defect in pulmonary function, but no evidence of respira- 
tory distress or of parenchymal lung disease in such patients 
(4). We hypothesized that CO* elimination is reduced when 
the velocity of chemical reaction between COZ and HCO; is 
decreased by inhibiting carbonic anhydrase (5,6). In this 
study, we compared the respiratory function of three 
patients, in whom carbonic anhydrase activity had been 
reported previously (l-3), with that of healthy volunteers. 
Case Histories 
Three patients were studied: patient A, a 27-year-old 
woman; patient B, a 30-year-old woman; and patient C, a 
36-year-old man (1,7). Only one (patient C) had con- 
sanguinous parents (first cousins). Osteopetrosis, attacks of 
muscle weakness associated with hypokalaemia, and meta- 
bolic acidosis (non-anion gap) occurred in all three. All 
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three had exercise intolerance due to the development of 
exertional tachypnoea and dyspnoea. Chest X-rays revealed 
dense ribcages and computed tomography (CT) of the head 
revealed multiple calcifications. All three had had repeated 
fractures of the legs which had healed slowly. Except for 
mental retardation, none had neurological abnormalities. 
Examination 
Respiratory function data were obtained in each of the 
three patients and compared with those of 10 healthy 
volunteers (five men and five women), aged 18-24 years. 
The following parameters were compared: body weight 
(BW), forced vital capacity (FVC), forced expiratory 
volume in 1 s (FEV& expired minute ventilation volume 
per body weight ( VE) and respiratory rate (RR) (Volume 
Monitor, Ohmeda 5420, Louisville Co., U.S.A.), tidal 
volume (TV), end-tidal PC02 (PETCO& CO2 concentration 
in end-tidal gas (FETCO~) (Oscar Oxy Datex, Copenhagen, 
Denmark), pH, PO2 (PaOz), PCOZ (PaCOz) and HCO; in 
arterial blood (ABL-III, Radiometer, Copenhagen, Den- 
mark). $‘COz and PO, and metabolic energy expenditure 
(EE, cal day-‘) in case C and volunteers were measured by 
metabolic monitor (Datex, Deltatrac, Helsinki, Finland). 
Arterial blood was obtained from the radial artery, and 
end-expiratory gas was collected through a face mask 
during bed-rest. The other parameters were then measured. 
Difference between PaCO2 and PETCO~ [(a-ET)PCO& and 
physiological VD/ VT, were calculated to evaluate respira- 
tory function. 
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Data Presentation 
Data on age, BW, vn, RR, TV, PETCO~, pH, PaOz, 
PaC02, HCO, and the difference between PaOz, and 
PaC02, (a- ET) X02, in volunteers are expressed as 
mean &SD. Data on the three patients are expressed as 
absolute values. 
Results 
The clinical characteristics of the patients and the 
volunteers are summarized in Table 1 and Fig. 1. The 
patients were older and lighter than the volunteers. 
FVC in the patients was lower than in the healthy adults 
although the FEVJFVC ratio was normal. All three 
patients had non-anion gap metabolic acidosis. Their VE 
and RR exceeded those of the volunteers and their TV was 
low. The patients exhibited lover PETCO~, pH, and HCOs- 
than the volunteers. The PaC02, values are normal. The 
PaCO, values in the patients, although they did not differ 
significantly from those in the volunteers, were near the 
upper limit of normal and were higher than expected 
for the pH level (Table 1). The patients exhibited higher 
(a - ET)PCOa values than the volunteers. Physiological 
VD/ VT in patient C was high. $‘COz and PO, in patients C 
were lower than in the volunteers, and EE in patient C and 
in the volunteers was lower than the predicted basal 
metabolic energy. 
Discussion 
Osteopetrosis with renal tubular acidosis and cerebral 
calcification was described in CA II deficiency by three 
independent groups in 1972 (&lo), and a number of 
subsequent cases have been reported (4, 11-15). Similar 
calcifications have been seen after the administration of 
massive doses of acetazolamide (100 mg kg-‘), an inhibitor 
of carbonic anhydrase (16). None of the reports have 
discussed any disturbances in CO2 elimination by the lungs, 
as might be expected, considering that CA inhibition can 
impair CO2 elimination in normal mammals (5, 6, 17). 
All three of our patients had mild restrictive lung disease 
and abnormally dense ribcages, which may suggest a type 
of chest-wall restriction. All three also had alveolar 
hyperventilation, as indicated by their low PETCO~ values. 
However, none of them had low PaC02 values and their 
acid-based status would classically be defined as mixed 
metabolic and respiratory acidosis. 
The elimination of COZ is controlled by ventilation, 
circulation and the conversion velocity of HCO, to CO*. 
0*12*0*01 
TABLE 1. Absolute values in three patients with a deficiency of CA II and mean values in 10 healthy volunteers 
Pateint A B C Volunteers (n = 10) 
BW (kg) 
HT (cm) 
FVC(1) 
%FVC 
FEVdl) 
FEV,/FVC 
VE kg-’ min-1)20 (1 
RR (time min-‘) 
TV (ml breath- ‘) 
PETCO~ (mmHg) 
PaC02 (mmHg) 
(a- ET)PC02 (mmHg) 
Physiological VD/ VT (%) 
PH 
HCO; (mEq 1 -I) 
POz(mHg) 
Na (mEq 1 - ‘) 
Cl (mEq 1-i) 
Anion (mEq l- ‘) gap 
liCOz (ml min- ‘) 
vO2 (ml min-‘) 
EE (cal day-‘) 
Basal metabolic energy (cal day- ‘) 
Haris-Benedict 
Fleisch 
39 42 47 58*8& 11.2 
150 130 148 
2.01 1.56 1.57 
71.0 63.9 44.6 
1.99 1.56 1.57 
99 100 100 
0.20 0.15 0.13 
19 20 24 14.2 f 3.3 
410 300 258 5005 169 
33.7 36 36 41*2*2*9 
38.4 46.3 45.8 42.5&t-2 
4.7 10.3 9.8 l-3& 1.3 
58.8 
7.261 7.218 7.252 7.389 f 0.023 
16.8 18.3 19.6 25.8 dzO.9 
110.8 99 89.1 
144 143 144 
114 109 116 
13.2 15.7 8.4 
164 173.8 & 16.9 
186 219.6+22.8 
1260 1488 146.4 f 
1330 1570*90 
1350 1519&85 
Data are given as means ( f SD). 
See text for abbreviations. 
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FIG. 1. Respiratory function parameters in three patients with a deficiency of CA II vs. 10 healthy volunteers. VE: minute 
ventilation volume per body weight (ml kg-’ min-‘); PETCO~: PCOz in end-expiratory gas; pH, PaCOz, and HCOa- were 
shown as the values in arterial blood; (a-ET)PCOz: difference between PaCOT and PETCO~. 
All three of our patients had high levels of minute 
ventilation and appropriately low PETCO~. The absence 
of carbonic anhydrase and the consequent impaired 
conversion of HCO; to COZ led to elevated PaC02 - 
&rC02, gradients, (a-ET) PCO2, ranging from 4.6 to 
10.3 mmHg (5, 6, 17, 18). These increased (a-ET)PCOz 
values, while above normal, are less than the gradients that 
have previously been observed after carbonic anhydrase 
inhibition (6). Our patients possibly had relatively high 
cardiac outputs, which helped to maintain low (a- ET) 
PC02 values, as has previously been observed in patients 
with hyperthyroidism and reduced carbonic anhydrase 
activity (19, 20). 
The excretion of CO2 can also be influenced by CA I in 
red cells and by pulmonary CA IV. The total CA activity in 
our patients may have been sufficient to deliver the CO2 
produced to the circulating erythrocytes and to eliminate 
CO2 from the lungs. The exercise intolerance seen in our 
patients may have been due to a failure of this system when 
CO2 production increased. 
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